The prefrontal cortex influence over subcortical and limbic regions governs antidepressant response by N=H/(M+R)

Psychiatry Research - Neuroimaging

Volumn 204, Issue 1, 2012, Pages 1-12

  Salerian, Alen Johannes ^a   Altar, Charles Anthony ^b,c  

^a The Salerian Center for Neuroscience and Pain   (United States)

^b NeuroDrug Consulting   (United States)

^c AssureRx HealthInc   (United States)

Author keywords

Amygdala; Antidepressant; Brain metabolism; Depression; Dorsolateral prefrontal cortex; Relapse

Indexed keywords

ANTIDEPRESSANT AGENT;

AMYGDALOID NUCLEUS; BRAIN METABOLISM; CINGULATE GYRUS; DRUG EFFICACY; EXECUTIVE FUNCTION; HIPPOCAMPUS; HUMAN; LIMBIC CORTEX; MAJOR DEPRESSION; PARAHIPPOCAMPAL GYRUS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REMISSION; REVIEW; SUBCORTEX; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; EXECUTIVE FUNCTION; HUMANS; LIMBIC SYSTEM; PREFRONTAL CORTEX;

EID: 84869879605     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2012.04.019     Document Type: Review

References (95)

1. Aihara M., Ida I., Yuuki N., Oshima A., Kumano H., Takahashi K., Fukuda M., Oriuchi N., Endo K., Matsuda H., Mikuni M. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Research: Neuroimaging 2007, 155:245-256.
2. Aizenstein H.J., Butters M.A., Wu M., Mazurkewicz L.M., Stenger V.A., Gianaros P.J., Becker J.T., Reynolds C.F., Carter C.S. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. American Journal of Geriatric Psychiatry 2009, 17:30-42.
3. Alexopoulos G.S. Role of executive function in late-life depression. Journal of Clinical Psychiatry 2003, 64(Suppl. 14):18-23.
4. Alexopoulos G.S., Murphy C.F., Gunning-Dixon F.M., Latoussakis V., Kanellopoulos D., Klimstra S., Lim K.O., Hoptman M.J. Microstructural white matter abnormalities and remission of geriatric depression. American Journal of Psychiatry 2008, 165:238-244.
5. Arnsten A.F. Development of the cerebral cortex: XIV. Stress impairs prefrontal cortical function. Journal of the American Academy of Child and Adolescent Psychiatry 1999, 38:220-222.
6. Arnsten A.F., Steere J.C., Hunt R.D. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Archives of General Psychiatry 1996, 53:448-455.
7. Bares M., Brunovsky M., Novak T., Kopecek M., Stopkova P., Sos P., Krajca V., Hoschl C. The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. European Neuropsychopharmacology 2010, 20:459-466.
8. Basso M.R., Bornstein R.A., Carona F., Morton R. Depression accounts for executive function deficits in obsessive-compulsive disorder. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 2001, 14:241-245.
9. Bench C.J., Frackowiak R.S., Dolan R.J. Changes in regional cerebral blood flow on recovery from depression. Psychological Medicine 1995, 25:247-261.
10. Biringer E., Lundervold A., Stordal K., Mykletun A., Egeland J., Bottlender R., Lund A. Executive function improvement upon remission of recurrent unipolar depression. European Archives of Psychiatry and Clinical Neurosciences 2005, 255:373-380.
11. Blumenfeld H., McNally K.A., Ostroff R.B., Zubal I.G. Targeted prefrontal cortical activation with bifrontal ECT. Psychiatry Research: Neuroimaging 2003, 123:165-170.
12. Bremner J.D., Elzinga B., Schmahl C., Vermetten E. Structural and functional plasticity of the human brain in posttraumatic stress disorder. Progress in Brain Research 2008, 167:171-186.
13. Brockmann H., Zobel A., Joe A., Biermann K., Scheef L., Schuhmacher A., von Widdern O., Metten M., Biersack H.J., Maier W., Boecker H. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression. Psychiatry Research: Neuroimaging 2009, 173:107-112.
14. Brody A.L., Saxena S., Mandelkern M.A., Fairbanks L.A., Ho M.L., Baxter L.R. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biological Psychiatry 2001, 50:171-178.
15. Brody A.L., Saxena S., Silverman D.H., Alborzian S., Fairbanks L.A., Phelps M.E., Huang S.C., Wu H.M., Maidment K., Baxter L.R. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Research: Neuroimaging 1999, 91:127-139.
16. Brody A.L., Saxena S., Stoessel P., Gillies L.A., Fairbanks L.A., Alborzian S., Phelps M.E., Huang S.C., Wu H.M., Ho M.L., Ho M.K., Au S.C., Maidment K., Baxter L.R. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Archives of General Psychiatry 2001, 58:631-640.
17. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979, 205:929-932.
18. Buchsbaum M.S., Wu J., Siegel B.V., Hackett E., Trenary M., Abel L., Reynolds C. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biological Psychiatry 1997, 41:15-22.
19. Carrion V.G., Weems C.F., Richert K., Hoffman B.C., Reiss A.L. Decreased prefrontal cortical volume associated with increased bedtime cortisol in traumatized youth. Biological Psychiatry 2010, 68:491-493.
20. Chan S.W., Norbury R., Goodwin G.M., Harmer C.J. Risk for depression and neural responses to fearful facial expressions of emotion. British Journal of Psychiatry 2009, 194:139-145.
21. Channon S., Green P.S. Executive function in depression: the role of performance strategies in aiding depressed and non-depressed participants. Journal of Neurology, Neurosurgery and Psychiatry 1999, 66:162-171.
22. Chen C.H., Suckling J., Ooi C., Fu C.H., Williams S.C., Walsh N.D., Mitterschiffthaler M.T., Pich E.M., Bullmore E. Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology 2008, 33:1909-1918.
23. Cho S.S., Strafella A.P. rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One 2009, 4:e6725.
24. Clark L., Sarna A., Goodwin G.M. Impairment of executive function but not memory in first-degree relatives of patients with bipolar I disorder and in euthymic patients with unipolar depression. American Journal of Psychiatry 2005, 162:1980-1982.
25. Davey C.G., Allen N.B., Harrison B.J., Yücel M. Increased amygdala response to positive social feedback in young people with major depressive disorder. Biological Psychiatry 2011, 69(8):734-741.
26. Devous M.D., Trivedi M.H., Rush A.J. Regional cerebral blood flow response to oral American phetamine challenge in healthy volunteers. Journal of Nuclear Medicine 2001, 42:535-542.
27. Dougherty D.D., Rauch S.L., Deckersbach T., Marci C., Loh R., Shin L.M., Alpert N.M., Fischman A.J., Fava M. Ventromedial prefrontal cortex and amygdala dysfunction during an anger induction positron emission tomography study in patients with major depressive disorder with anger attacks. Archives of General Psychiatry 2004, 61:795-804.
28. Drevets W.C. Prefrontal cortical-amygdalar metabolism in major depression. Annals of the New York Academy of Sciences 1999, 877:614-637.
29. Drevets W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Progress in Brain Research 2000, 126:413-431.
30. Drevets W.C., Bogers W., Raichle M.E. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. European Neuropsychopharmacology 2002, 12:527-544.
31. Drevets W.C., Price J.L., Bardgett M.E., Reich T., Todd R.D., Raichle M.E. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacology, Biochemistry and Behavior 2002, 71:431-447.
32. Eschweiler G.W., Vonthein R., Bode R., Huell M., Conca A., Peters O., Mende-Lechler S., Peters J., Klecha D., Prapotnik M., DiPauli J., Wild B., Plewnia C., Bartels M., Schlotter W. Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): a short-term randomised controlled trial in pharmaco-resistant major depression. Journal of Affective Disorders 2007, 101:149-157.
33. Fitzgerald P.B., Laird A.R., Maller J., Daskalakis Z.J. A meta-analytic study of changes in brain activation in depression. Human Brain Mapping 2008, 29:683-695.
34. Fitzgerald P.B., Srithiran A., Benitez J., Daskalakis Z.Z., Oxley T.J., Kulkarni J., Egan G.F. An fMRI study of prefrontal brain activation during multiple tasks in patients with major depressive disorder. Human Brain Mapping 2008, 29:490-501.
35. Furmark T., Tillfors M., Marteinsdottir I., Fischer H., Pissiota A., Langstrom B., Fredrikson M. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Archives of General Psychiatry 2002, 59:425-433.
36. Gibb B.E., Chelminski I., Zimmerman M. Childhood emotional, physical, and sexual abuse, and diagnoses of depressive and anxiety disorders in adult psychiatric outpatients. Depression and Anxiety 2007, 24:256-263.
37. Goldapple K., Segal Z., Garson C., Lau M., Bieling P., Kennedy S., Mayberg H. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry 2004, 61:34-41.
38. Hansen P.E., Ravnkilde B., Videbech P., Clemmensen K., Sturlason R., Reiner M., Parner E., Rosenberg R., Vestergaard P. Low-frequency repetitive transcranial magnetic stimulation inferior to electroconvulsive therapy in treating depression. Journal of ECT 2011, 27(1):26-32.
39. Hasler G., Fromm S., Carlson P.J., Luckenbaugh D.A., Waldeck T., Geraci M., Roiser J.P., Neumeister A., Meyers N., Charney D.S., Drevets W.C. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Archives of General Psychiatry 2008, 65:521-531.
40. Heikman P., Salmelin R., Makela J.P., Hari R., Katila H., Kuoppasalmi K. Relation between frontal 3-7Hz MEG activity and the efficacy of ECT in major depression. Journal of ECT 2001, 17:136-140.
41. Jalenques I., Legrand G., Vaille-Perret E., Tourtauchaux R., Galland F. Therapeutic efficacy and safety of repetitive transcranial magnetic stimulation in depressions of the elderly: a review. Encephale 2010, 36(Suppl. 2):D105-118.
42. Johnstone T., van Reekum C.M., Urry H.L., Kalin N.H., Davidson R.J. Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. Journal of Neuroscience 2007, 27:8877-8884.
43. Kawahara Y., Kawahara H., Kaneko F., Tanaka M. Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology (Berlin) 2007, 194:73-81.
44. Kennedy S.H., Evans K.R., Kruger S., Mayberg H.S., Meyer J.H., McCann S., Arifuzzman A.I., Houle S., Vaccarino F.J. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. American Journal of Psychiatry 2001, 158:899-905.
45. Kennedy S.H., Konarski J.Z., Segal Z.V., Lau M.A., Bieling P.J., McIntyre R.S., Mayberg H.S. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. American Journal of Psychiatry 2007, 164:778-788.
46. Ketter T.A., Kimbrell T.A., George M.S., Dunn R.T., Speer A.M., Benson B.E., Willis M.W., Danielson A., Frye M.A., Herscovitch P., Post R.M. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biological Psychiatry 2001, 49(2):97-109.
47. Kimbrell T.A., Ketter T.A., George M.S., Little J.T., Benson B.E., Willis M.W., Herscovitch P., Post R.M. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biological Psychiatry 2002, 51:237-252.
48. Kohn Y., Freedman N., Lester H., Krausz Y., Chisin R., Lerer B., Bonne O. 99mTc-HMPAO SPECT study of cerebral perfusion after treatment with medication and electroconvulsive therapy in major depression. Journal of Nuclear Medicine 2007, 48:1273-1278.
49. Kohn Y., Freedman N., Lester H., Krausz Y., Chisin R., Lerer B., Bonne O. Cerebral perfusion after a 2-year remission in major depression. International Journal of Neuropsychopharmacology 2008, 11:837-843.
50. Konarski J.Z., Kennedy S.H., McIntyre R.S., Rafi-Tari S., Soczynska J.K., Mayberg H.S. Relationship between regional brain metabolism, illness severity and age in depressed subjects. Psychiatry Research: Neuroimaging 2007, 155:203-210.
51. Lavretsky H., Roybal D.J., Ballmaier M., Toga A.W., Kumar A. Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. Journal of Clinical Psychiatry 2005, 66:964-967.
52. Levkovitz Y., Harel E.V., Roth Y., Braw Y., Most D., Katz L.N., Sheer A., Gersner R., Zangen A. Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. Brain Stimulation 2009, 2(4):188-200.
53. Li C.T., Lin C.P., Chou K.H., Chen I.Y., Hsieh J.C., Wu C.L., Lin W.C., Su T.P. Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. NeuroImage 2010, 50:347-356.
54. Little J.T., Ketter T.A., Kimbrell T.A., Dunn R.T., Benson B.E., Willis M.W., Luckenbaugh D.A., Post R.M. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biological Psychiatry 2005, 57:220-228.
55. MacMillan S., Szeszko P.R., Moore G.J., Madden R., Lorch E., Ivey J., Banerjee S.P., Rosenberg D.R. Increased amygdala: hippocampal volume ratios associated with severity of anxiety in pediatric major depression. Journal of Child and Adolescent Psychopharmacology 2003, 13:65-73.
56. Mayberg H.S. Limbic-cortical dysregulation: a proposed model of depression. Journal of Neuropsychiatry and Clinical Neurosciences 1997, 9:471-481.
57. Mayberg H.S. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. British Medical Bulletin 2003, 65:193-207.
58. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., Jerabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry 2000, 48:830-843.
59. Mayberg H.S., Lozano A., Voon V., Kennedy S., McNeely H., Hamani C., Schwalb J., Seminowicz D. Deep Brain Stimulation for Treatment Resistant Depression. Neuron 2005, 45:651-660.
60. Mayberg H.S., Liotti M., Brannan S.K., McGinnis S., Mahurin R.K., Jerabek P.A., Silva J.A., Tekell J.L., Martin C.C., Lancaster J.L., Fox P.T. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. American Journal of Psychiatry 1999, 156:675-682.
61. Millan M.J., Gobert A., Lejeune F., Dekeyne A., Newman-Tancredi A., Pasteau V., Rivet J.M., Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 2003, 306:954-964.
62. Millan M.J., Gobert A., Rivet J.M., Adhumeau-Auclair A., Cussac D., Newman-Tancredi A., Dekeyne A., Nicolas J.P., Lejeune F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. European Journal of Neuroscience 2000, 12:1079-1095.
63. Milo T.J., Kaufman G.E., Barnes W.E., Konopka L.M., Crayton J.W., Ringelstein J.G., Shirazi P.H. Changes in regional cerebral blood flow after electroconvulsive therapy for depression. Journal of ECT 2001, 17:15-21.
64. Morgan M.A., Romanski L.M., LeDoux J.E. Extinction of emotional learning: contribution of medial prefrontal cortex. Neuroscience Letters 1993, 163:109-113.
65. Morimoto S.S., Gunning F.M., Murphy C.F., Kanellopoulos D., Kelly R.E., Alexopoulos G.S. Executive function and short-term remission of geriatric depression: the role of semantic strategy. American Journal of Geriatric Psychiatry 2010.
66. Nahas Z., Anderson B.S., Borckardt J., Arana A.B., George M.S., Reeves S.T., Takacs I. Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression. Biological Psychiatry 2010, 67:101-109.
67. Nahas Z., Lomarev M., Roberts D.R., Shastri A., Lorberbaum J.P., Teneback C., McConnell K., Vincent D.J., Li X., George M.S., Bohning D.E. Unilateral left prefrontal transcranial magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by interleaved BOLD fMRI. Biological Psychiatry 2001, 50:712-720.
68. New A.S., Buchsbaum M.S., Hazlett E.A., Goodman M., Koenigsberg H.W., Lo J., Iskander L., Newmark R., Brand J., O'Flynn K., Siever L.J. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berlin) 2004, 176:451-458.
69. Ogura A., Morinobu S., Kawakatsu S., Totsuka S., Komatani A. Changes in regional brain activity in major depression after successful treatment with antidepressant drugs. Acta Psychiatrica Scandinavica 1998, 98:54-59.
70. Ohnishi T., Matsuda H., Imabayashi E., Okabe S., Takano H., Arai N., Ugawa Y. rCBF changes elicited by rTMS over DLPFC in humans. Supplements to Clinical Neurophysiology 2004, 57:715-720.
71. Paus T., Barrett J. Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression. Journal of Psychiatry and Neuroscience 2004, 29:268-279.
72. Pizzagalli D.A. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011, 36:183-206.
73. Salvadore G., Cornwell B.R., Sambataro F., Latov D., Colon-Rosario V., Carver F., Holroyd T., DiazGranados N., Machado-Vieira R., Grillon C., Drevets W.C., Zarate C.A. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010, 35:1415-1422.
74. San L., Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European Psychiatry 2008, 23:396-402.
75. Savitz J., Drevets W.C. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neuroscience and Biobehavioral Reviews 2009, 33:699-771.
76. Saxena S., Brody A.L., Ho M.L., Zohrabi N., Maidment K.M., Baxter L.R. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. American Journal of Psychiatry 2003, 160:522-532.
77. Schraml F.V., Beason-Held L.L. Technetium-99m ethyl cysteinate dimer (ECD) cerebral accumulation and symptom and sign severity during hypothyroidism. Neurocrine Endocrinology Letters 2010, 31:161-167.
78. Seminowicz D.A., Mayberg H.S., McIntosh A.R., Goldapple K., Kennedy S., Segal Z., Rafi-Tari S. Limbic-frontal circuitry in major depression: a path modeling metanalysis. NeuroImage 2004, 22:409-418.
79. Sheline Y.I., Barch D.M., Donnelly J.M., Ollinger J.M., Snyder A.Z., Mintun M.A. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biological Psychiatry 2001, 50:651-658.
80. Shin L.M., Orr S.P., Carson M.A., Rauch S.L., Macklin M.L., Lasko N.B., Peters P.M., Metzger L.J., Dougherty D.D., Cannistraro P.A., Alpert N.M., Fischman A.J., Pitman R.K. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Archives of General Psychiatry 2004, 61:168-176.
81. Shin L.M., Wright C.I., Cannistraro P.A., Wedig M.M., McMullin K., Martis B., Macklin M.L., Lasko N.B., Cavanagh S.R., Krangel T.S., Orr S.P., Pitman R.K., Whalen P.J., Rauch S.L. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Archives of General Psychiatry 2005, 62:273-281.
82. Siegle G.J., Carter C.S., Thase M.E. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. American Journal of Psychiatry 2006, 163:735-738.
83. Spinhoven P., Elzinga B.M., Hovens J.G., Roelofs K., Zitman F.G., van Oppen P., Penninx B.W. The specificity of childhood adversities and negative life events across the life span to anxiety and depressive disorders. Journal of Affective Disorders 2010, 126:103-112.
84. Stahl S.M., Fava M., Trivedi M.H., Caputo A., Shah A., Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2010, 71:616-626.
85. Swartz C.M. Asymmetric bilateral right frontotemporal left frontal stimulus electrode placement for electroconvulsive therapy. Neuropsychobiology 1994, 29:174-178.
86. Takano H., Kato M., Inagaki A., Watanabe K., Kashima H. Time course of cerebral blood flow changes following electroconvulsive therapy in depressive patients-measured at 3 time points using single photon emission computed tomography. Keio Journal of Medicine 2006, 55:153-160.
87. Teneback C.C., Nahas Z., Speer A.M., Molloy M., Stallings L.E., Spicer K.M., Risch S.C., George M.S. Changes in prefrontal cortex and paralimbic activity in depression following two weeks of daily left prefrontal TMS. Journal of Neuro-psychiatry and Clinical Neurosciences 1999, 11:426-435.
88. Tsaltas E., Kalogerakou S., Papakosta V.M., Kontis D., Theochari E., Koutroumpi M., Anyfandi E., Michopoulos I., Poulopoulou C., Papadimitriou G., Oulis P. Contrasting patterns of deficits in visuospatial memory and executive function in patients with major depression with and without ECT referral. Psychological Medicine 2010, 1-13.
89. Valdizan E.M., Diez-Alarcia R., Gonzalez-Maeso J., Pilar-Cuellar F., Garcia-Sevilla J.A., Meana J.J., Pazos A. alpha-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims. Biological Psychiatry 2010, 68:869-872.
90. van Harmelen A.L., van Tol M.J., van der Wee N.J., Veltman D.J., Aleman A., Spinhoven P., van Buchem M.A., Zitman F.G., Penninx B.W., Elzinga B.M. Reduced medial prefrontal cortex volume in adults reporting childhood emotional maltreatment. Biological Psychiatry 2010, 68:832-838.
91. Vasic N., Walter H., Sambataro F., Wolf R.C. Aberrant functional connectivity of dorsolateral prefrontal and cingulate networks in patients with major depression during working memory processing. Psychological Medicine 2009, 39:977-987.
92. Wagner G., Koch K., Schachtzabel C., Reichenbach J.R., Sauer H., Schlosser Md, R.G. Enhanced rostral anterior cingulate cortex activation during cognitive control is related to orbitofrontal volume reduction in unipolar depression. Journal of Psychiatry and Neuroscience 2008, 33:199-208.
93. Weniger G., Lange C., Irle E. Abnormal size of the amygdala predicts impaired emotional memory in major depressive disorder. Journal of Affective Disorders 2006, 94:219-229.
94. Wernicke J.F., Ossanna M.J. The placebo response in pain and depression: in search of a common pathway. Frontiers in Bioscience (Scholar Edition) 2010, 2:106-111.
95. Windischberger C., Lanzenberger R., Holik A., Spindelegger C., Stein P., Moser U., Gerstl F., Fink M., Moser E., Kasper S. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. NeuroImage 2010, 49:1161-1170.